治疗成人慢性和发作性偏头痛的药物干预的不良和严重不良事件发生率:系统性综述

IF 2.1 Q3 CLINICAL NEUROLOGY
Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry
{"title":"治疗成人慢性和发作性偏头痛的药物干预的不良和严重不良事件发生率:系统性综述","authors":"Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry","doi":"10.1136/bmjno-2023-000616","DOIUrl":null,"url":null,"abstract":"Background Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs. Method We systematically searched for published randomised controlled trials (RCTs) using terms for migraine/headache and preventive medications. Using eligibility criteria, two reviewers independently assessed the articles. Cochrane risk-of-bias tool was applied to assess the quality of the studies. Data were classified by system organ class (SOC). Results Thirty-two RCTs with 21 780 participants met the eligibility criteria for the incidence of adverse events (AEs). Additionally, 33 RCTs with 22 615 participants were included to synthesise the incidence of serious AEs (SAEs). The percentage of attributed AEs and SAEs to each SOC for 10 preventive drugs with different dosing regimens was calculated. Amitriptyline and topiramate had a higher incidence of nervous system disorders; Topiramate was also associated with a higher incidence of psychiatric disorders. All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate. BTA had a higher incidence of musculoskeletal disorders than the other drugs. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs. Conclusion Notably, the observed harm to SOCs varies among these preventive drugs. We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and/or chronic migraine populations. PROSPERO registration number CRD42021265993. All data relevant to the study are included in the article or uploaded as supplementary information.","PeriodicalId":52754,"journal":{"name":"BMJ Neurology Open","volume":"211 1","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review\",\"authors\":\"Seyran Naghdi, Martin Underwood, Anna Brown, Manjit Matharu, Callum Duncan, Natasha Davies, Aiva Aksentyte, Hema Mistry\",\"doi\":\"10.1136/bmjno-2023-000616\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs. Method We systematically searched for published randomised controlled trials (RCTs) using terms for migraine/headache and preventive medications. Using eligibility criteria, two reviewers independently assessed the articles. Cochrane risk-of-bias tool was applied to assess the quality of the studies. Data were classified by system organ class (SOC). Results Thirty-two RCTs with 21 780 participants met the eligibility criteria for the incidence of adverse events (AEs). Additionally, 33 RCTs with 22 615 participants were included to synthesise the incidence of serious AEs (SAEs). The percentage of attributed AEs and SAEs to each SOC for 10 preventive drugs with different dosing regimens was calculated. Amitriptyline and topiramate had a higher incidence of nervous system disorders; Topiramate was also associated with a higher incidence of psychiatric disorders. All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate. BTA had a higher incidence of musculoskeletal disorders than the other drugs. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs. Conclusion Notably, the observed harm to SOCs varies among these preventive drugs. We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and/or chronic migraine populations. PROSPERO registration number CRD42021265993. All data relevant to the study are included in the article or uploaded as supplementary information.\",\"PeriodicalId\":52754,\"journal\":{\"name\":\"BMJ Neurology Open\",\"volume\":\"211 1\",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMJ Neurology Open\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/bmjno-2023-000616\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Neurology Open","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjno-2023-000616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景偏头痛是全球第二大常见疾病,也是导致残疾的首要原因之一,造成了巨大的经济负担。许多预防偏头痛的药物都有明显的副作用,会影响不同的身体器官。方法 我们以偏头痛/头痛和预防性药物为关键词,系统地检索了已发表的随机对照试验(RCT)。根据资格标准,由两名审稿人对文章进行独立评估。采用 Cochrane 偏倚风险工具评估研究质量。数据按系统器官等级(SOC)进行分类。结果 32 项 RCT 共 21 780 名参与者符合不良事件(AEs)发生率的资格标准。此外,还纳入了 33 项 RCT,共 22 615 名参与者,以综合分析严重 AE(SAE)的发生率。我们计算了不同给药方案的 10 种预防性药物的 AE 和 SAE 在每种 SOC 中所占的百分比。阿米替林和托吡酯的神经系统疾病发生率较高;托吡酯的精神疾病发生率也较高。所有药物都有一定的感染和侵袭发生率,其中奥那布毒毒素 A(BTA)的感染和侵袭发生率最低。与其他药物相比,BTA 的肌肉骨骼疾病发病率较高。与其他药物相比,降钙素基因相关肽(CGRP)单克隆抗体(MAbs)(如 fremanezumab 和 galcanezumab)与更多的一般疾病和用药部位病症有关。结论 值得注意的是,在这些预防性药物中,观察到的对 SOC 的危害各不相同。我们建议进行头对头 RCT 研究,以评估口服药物、BTA 和 CGRP MAbs 在发作性和/或慢性偏头痛人群中的安全性。PROSPERO 注册号为 CRD42021265993。与该研究相关的所有数据均包含在文章中或作为补充信息上传。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review
Background Migraine is the second most common prevalent disorder worldwide and is a top cause of disability with a substantial economic burden. Many preventive migraine medications have notable side effects that affect different body organs. Method We systematically searched for published randomised controlled trials (RCTs) using terms for migraine/headache and preventive medications. Using eligibility criteria, two reviewers independently assessed the articles. Cochrane risk-of-bias tool was applied to assess the quality of the studies. Data were classified by system organ class (SOC). Results Thirty-two RCTs with 21 780 participants met the eligibility criteria for the incidence of adverse events (AEs). Additionally, 33 RCTs with 22 615 participants were included to synthesise the incidence of serious AEs (SAEs). The percentage of attributed AEs and SAEs to each SOC for 10 preventive drugs with different dosing regimens was calculated. Amitriptyline and topiramate had a higher incidence of nervous system disorders; Topiramate was also associated with a higher incidence of psychiatric disorders. All drugs showed a certain incidence of infections and infestations, with Onabotulinumtoxin A (BTA) having the lowest rate. BTA had a higher incidence of musculoskeletal disorders than the other drugs. Calcitonin gene-related peptide (CGRP) monoclonal antibodies (MAbs) such as fremanezumab and galcanezumab were linked to more general disorders and administration site conditions than other drugs. Conclusion Notably, the observed harm to SOCs varies among these preventive drugs. We suggest conducting head-to-head RCTs to evaluate the safety profile of oral medications, BTA, and CGRP MAbs in episodic and/or chronic migraine populations. PROSPERO registration number CRD42021265993. All data relevant to the study are included in the article or uploaded as supplementary information.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BMJ Neurology Open
BMJ Neurology Open Medicine-Neurology (clinical)
CiteScore
3.20
自引率
3.70%
发文量
46
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信